Revisto

Revisto offers a specialized software-as-a-service (SaaS) platform designed to streamline the marketing compliance process for the pharmaceutical and life sciences industries. Founded in 2023 by CEO Ferry Tamtoro and Chief Data Officer Jaya Plmanabhan, the company is headquartered in San Antonio, Texas. Tamtoro brings over two decades of experience in healthcare technology, particularly in the pharmaceutical and medical device sectors, having previously co-founded BrightInsight, a platform for regulated digital health solutions. Plmanabhan has an extensive background in leveraging machine learning and data science to build scalable solutions for drug discovery, clinical trials, and patient engagement.

The company's core business revolves around its AI-powered platform that accelerates the Medical, Legal, and Regulatory (MLR) review of promotional materials—a traditionally manual and time-consuming process for pharmaceutical companies. Revisto's technology analyzes marketing content against a backdrop of real-time FDA regulations, proprietary pharmaceutical data, and a client's own brand-specific standards and historical review actions. This allows creative teams to receive compliance and quality feedback early in the content creation process, significantly reducing delays and the costs associated with them. The platform is built to integrate with existing content management systems used by pharmaceutical companies, such as Veeva Vault PromoMats. By automating and optimizing these workflows, Revisto aims to help life sciences companies reduce their time-to-market for new promotional materials, potentially saving millions per brand annually.

The business operates on a B2B model, targeting pharmaceutical and life sciences companies as its primary clients. Its revenue is generated through this enterprise software offering. The company's value proposition has attracted significant investor interest, including from major industry players. In November 2024, Revisto announced a $4 million seed funding round led by LiveOak Ventures, with participation from Eli Lilly and Company, Tau Ventures, and Arkin Digital Health, bringing its total funding to $6 million. This capital is intended to expand the team and accelerate product development to further enhance the capabilities of its AI engine.

Keywords: pharmaceutical marketing, life sciences compliance, MLR review automation, medical legal regulatory, RegTech, AI in pharma, marketing compliance software, content review platform, Ferry Tamtoro, Jaya Plmanabhan, LiveOak Ventures, Eli Lilly and Company, promotional material review, FDA compliance, AdTech, SaaS, Marketing Tech, Artificial Intelligence, Machine Learning, brand compliance, digital health solutions, Veeva integration